Meta-analysis of the Clinical and Immunopathological Characteristics and Treatment Outcomes in Epidermolysis Bullosa Acquisita Patients

Overview

Journal Orphanet J Rare Dis

Publisher Biomed Central

Specialty General Medicine

Date 2018 Sep 6

PMID 30180870

Citations 29

Authors

Hiroaki Iwata

Artem Vorobyev

Hiroshi Koga

Andreas Recke

Detlef Zillikens

Catherine Prost-Squarcioni

Norito Ishii

Takashi Hashimoto

Ralf J Ludwig

Affiliations

Soon will be listed here.

Abstract

Background: Epidermolysis bullosa acquisita (EBA) is an orphan autoimmune disease. Several clinical phenotypes have been described, but subepidermal blistering is characteristic of all variants. Limited data on clinical and immunopathological characteristics and treatment outcomes in EBA are available. To fill this gap, we collected this information from EBA cases, meeting current diagnostic criteria, published between 1971 and 2016.

Results: We identified 1159 EBA cases. This number must be, however, interpreted with caution, as it is not possible to check for multiple reporting. The analysis of all cases indicated that EBA affects all age groups (median: 50 years, range: 1 to 94 years) at an equal gender distribution. Non-mechanobullous (non-MB) forms of EBA were observed in 55% of patients, whereas the mechanobullous variant (MB-EBA) or a combination of both variants was described in 38 or 7% of patients, respectively. Type VII collagen (COL7)-specific autoantibodies were primarily of the IgG isotype, but anti-COL7 IgA, IgM and IgE were also documented. Comparison of the 2 clinical EBA types showed a higher frequency of IgA deposits in non-MB EBA as opposed to MB EBA. Mucous membrane involvement was observed in 23% of patients, and 4.4% of cases were associated with other chronic inflammatory diseases. Of note, IgA deposits were more frequently observed in cases with mucous membrane involvement. Our analysis indicated that EBA is difficult to treat and that the choice of treatment varies widely. Chi square was applied to identify medications associated with complete remission (CR). Considering all EBA cases, intravenous immunoglobulin (IVIG, p = 0.0047) and rituximab (p = 0.0114) were associated with CR. Subgroup analysis demonstrated that no treatment was associated with CR for non-MB EBA, while IVIG (p = 0.003) was associated with CR in MB EBA.

Conclusions: Within the limitations of the study, we here document the clinical and immunopathological characteristics and treatment outcomes in a large cohort of EBA patients. The observed associations of single drugs with treatment outcome may serve as a guide to develop clinical trials.

Citing Articles

Linear IgA bullous dermatosis-a fifty year experience of Warsaw Center of bullous diseases.

Kowalewski C, Wozniak K Front Immunol. 2025; 15:1478318.

PMID: 39877369 PMC: 11772161. DOI: 10.3389/fimmu.2024.1478318.

Rituximab in the Treatment of Epidermolysis Bullosa Acquisita: A Systematic Review.

Kianfar N, Dasdar S, Marashi A, Tavakolpour S, Mahmoudi H, Daneshpazhooh M J Clin Aesthet Dermatol. 2024; 17(7):24-36.

PMID: 39006807 PMC: 11238708.

IgM-mediated epidermolysis bullosa acquisita.

Harrison S, Mayes V, Brimhall C, King R JAAD Case Rep. 2024; 46:49-51.

PMID: 38510834 PMC: 10951440. DOI: 10.1016/j.jdcr.2024.01.004.

Rituximab in the Management of Autoimmune Bullous Diseases: A Treatment-Resistant Case Series from a Single Central European Referral Center.

Spalek M, Jalowska M, Bowszyc-Dmochowska M, Dmochowski M Medicina (Kaunas). 2024; 60(2).

PMID: 38399557 PMC: 10890531. DOI: 10.3390/medicina60020270.

Clinical Features of Paediatric Inflammatory Epidermolysis Bullosa Acquisita: A Case Series Study.

Zhang Y, Dang J, Li R, Chen X, Zhu X, Wang M Acta Derm Venereol. 2024; 104:adv11917.

PMID: 38270257 PMC: 10831865. DOI: 10.2340/actadv.v104.11917.

References

Schmidt E, Zillikens D . Pemphigoid diseases. Lancet. 2012; 381(9863):320-32. DOI: 10.1016/S0140-6736(12)61140-4. View

Satoh M, Chan E, Ho L, Rose K, Parks C, Cohn R . Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum. 2012; 64(7):2319-27. PMC: 3330150. DOI: 10.1002/art.34380. View

Yan T, He C, Hua B, Li L, Jin H, Liu Y . Coexistence of acquired hemophilia A and epidermolysis bullosa acquisita: Two case reports and published work review. J Dermatol. 2016; 44(1):76-79. DOI: 10.1111/1346-8138.13546. View

Wetzels R, Robben H, Leigh I, Schaafsma H, Vooijs G, Ramaekers F . Distribution patterns of type VII collagen in normal and malignant human tissues. Am J Pathol. 1991; 139(2):451-9. PMC: 1886065. View

Engineer L, Ahmed A . Emerging treatment for epidermolysis bullosa acquisita. J Am Acad Dermatol. 2001; 44(5):818-28. DOI: 10.1067/mjd.2001.113693. View

de Jong M, Bruins S, Heeres K, Jonkman M, Nieboer C, Boorsma D . Bullous pemphigoid and epidermolysis bullosa acquisita. Differentiation by fluorescence overlay antigen mapping. Arch Dermatol. 1996; 132(2):151-7. DOI: 10.1001/archderm.132.2.151. View

Hirose M, Tiburzy B, Ishii N, Pipi E, Wende S, Rentz E . Effects of intravenous immunoglobulins on mice with experimental epidermolysis bullosa acquisita. J Invest Dermatol. 2014; 135(3):768-775. DOI: 10.1038/jid.2014.453. View

Caux F, Kirtschig G, Lemarchand-Venencie F, Venencie P, Hoang-Xuan T, Robin H . IgA-epidermolysis bullosa acquisita in a child resulting in blindness. Br J Dermatol. 1997; 137(2):270-5. DOI: 10.1046/j.1365-2133.1997.18191915.x. View

Aractingi S, Bachmeyer C, Prost C, Caux F, Flageul B, Fermand J . Subepidermal autoimmune bullous skin diseases associated with B-cell lymphoproliferative disorders. Medicine (Baltimore). 1999; 78(4):228-35. DOI: 10.1097/00005792-199907000-00003. View

10.

Shaw M, McKee P, Gaminara E, Pearson T, Evans B, McGibbon D . Epidermolysis bullosa acquisita associated with chronic lymphatic leukaemia. Clin Exp Dermatol. 1985; 10(2):162-8. DOI: 10.1111/j.1365-2230.1985.tb00546.x. View

11.

Hayashi N, Koshiba M, Nishimura K, Sugiyama D, Nakamura T, Morinobu S . Prevalence of disease-specific antinuclear antibodies in general population: estimates from annual physical examinations of residents of a small town over a 5-year period. Mod Rheumatol. 2008; 18(2):153-60. DOI: 10.1007/s10165-008-0028-1. View

12.

GAMMON W, Briggaman R, Woodley D, Heald P, WHEELER Jr C . Epidermolysis bullosa acquisita--a pemphigoid-like disease. J Am Acad Dermatol. 1984; 11(5 Pt 1):820-32. DOI: 10.1016/s0190-9622(84)80459-4. View

13.

Nieboer C, Boorsma D, WOERDEMAN M, Kalsbeek G . Epidermolysis bullosa acquisita. Immunofluorescence, electron microscopic and immunoelectron microscopic studies in four patients. Br J Dermatol. 1980; 102(4):383-92. DOI: 10.1111/j.1365-2133.1980.tb06550.x. View

14.

Etienne A, Ruffieux P, Didierjean L, Saurat J . [Epidermolysis bullosa acquisita and metastatic cancer of the uterine cervix]. Ann Dermatol Venereol. 1998; 125(5):321-3. View

15.

Livden J, Nilsen R, THUNOLD S, Schjonsby H . Epidermolysis bullosa acquisita and Crohn's disease. Acta Derm Venereol. 1978; 58(3):241-4. View

16.

Licarete E, Ganz S, Recknagel M, Di Zenzo G, Hashimoto T, Hertl M . Prevalence of collagen VII-specific autoantibodies in patients with autoimmune and inflammatory diseases. BMC Immunol. 2012; 13:16. PMC: 3368718. DOI: 10.1186/1471-2172-13-16. View

17.

Hughes B, Horne J . Epidermolysis bullosa acquisita and total ulcerative colitis. J R Soc Med. 1988; 81(8):473-5. PMC: 1291723. DOI: 10.1177/014107688808100821. View

18.

Zumelzu C, Le Roux-Villet C, Loiseau P, Busson M, Heller M, Aucouturier F . Black patients of African descent and HLA-DRB1*15:03 frequency overrepresented in epidermolysis bullosa acquisita. J Invest Dermatol. 2011; 131(12):2386-93. DOI: 10.1038/jid.2011.231. View

19.

Buijsrogge J, Diercks G, Pas H, Jonkman M . The many faces of epidermolysis bullosa acquisita after serration pattern analysis by direct immunofluorescence microscopy. Br J Dermatol. 2011; 165(1):92-8. DOI: 10.1111/j.1365-2133.2011.10346.x. View

20.

Saleh M, Ishii K, Kim Y, Murakami A, Ishii N, Hashimoto T . Development of NC1 and NC2 domains of type VII collagen ELISA for the diagnosis and analysis of the time course of epidermolysis bullosa acquisita patients. J Dermatol Sci. 2011; 62(3):169-75. DOI: 10.1016/j.jdermsci.2011.03.003. View